Order Article Reprints

Diamantopoulos PT, Kontandreopoulou C-N, Gkoufa A, Solomou E, Anastasopoulou A, Palli E, Kouzis P, Bouros S, Samarkos M, Magiorkinis G, et al. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy. Cancers. 2022; 14(15):3791. https://doi.org/10.3390/cancers14153791

Diamantopoulos, Panagiotis T., Christina-Nefeli Kontandreopoulou, Aikaterini Gkoufa, Elena Solomou, Amalia Anastasopoulou, Eleni Palli, Panagiotis Kouzis, Spyros Bouros, Mihalis Samarkos, Gkikas Magiorkinis, and et al. 2022. "Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy" Cancers 14, no. 15: 3791. https://doi.org/10.3390/cancers14153791

Diamantopoulos, P. T., Kontandreopoulou, C. -N., Gkoufa, A., Solomou, E., Anastasopoulou, A., Palli, E., Kouzis, P., Bouros, S., Samarkos, M., Magiorkinis, G., & Gogas, H. (2022). Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy. Cancers, 14(15), 3791. https://doi.org/10.3390/cancers14153791